Author

R. L. Beijersbergen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

C. Lieftink· 4 shared A. Velds· 2 shared B. Morris· 2 shared E. Gogola· 2 shared F. Jochems· 2 shared G. De Conti· 2 shared J. Bhin· 2 shared J. Jonkers· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

C. Lieftink

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

J. Bhin, M. Paes Dias, E. Gogola, F. Rolfs, S. R. Piersma, R. de Bruijn, J. de Ruiter, B. van den Broek, A. Duarte, W. Sol, I. van der Heijden, L. Bakker, T. S. Kaiponen, C. Lieftink, B. Morris, , J. Jonkers

bioRxiv · Sep 7, 2022Cancer Biology

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

Z. Pogacar, K. Groot, F. Jochems, M. Dos Santos Dias, B. Morris, M. Roosen, L. Wardak, G. De Conti, A. Velds, C. Lieftink, R. L. Beijersbergen, R. Bernards, R. Leite de Oliveira

This study identifies genetic and compound factors that modulate cancer cell response to the drug indisulam, revealing therapeutic strategies for its clinical reuse.

bioRxiv · Dec 20, 2021Cancer Biology

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

Z. Pogacar, J. L. Johnson, L. Krenning, G. De Conti, C. Lieftink, A. Velds, L. Wardak, F. Jochems, K. Groot, A. Schepers, L. Wang, J.-Y. Song, M. van de Ven, O. van Tellingen, R. H. Medema, , R. Leite de Oliveira

The paper identifies that combining indisulam with palbociclib enhances senescence in cancer cells by inhibiting CDK2 kinase activity.

bioRxiv · Oct 18, 2021Cancer Biology

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps

M. Paes Dias, V. Tripathi, I. v. d. Heijden, K. Cong, E.-M. Manolika, J. Bhin, E. Gogola, P. Galanos, S. Annunziato, C. Lieftink, M. Andujar-Sanchez, S. Chakrabarty, G. C. M. Smith, M. v. d. Ven, R. L. Beijersbergen, , J. Jonkers

This study identifies loss of LIG3 as a factor that reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by increasing ssDNA gaps.

bioRxiv · Mar 24, 2021 · PreprintCancer Biology